AI Engines For more Details: Perplexity Kagi Labs You
Motion Sickness: Cyclizine hydrochloride is commonly used for the prevention and treatment of motion sickness, a condition characterized by nausea, vomiting, and dizziness experienced during travel, particularly in vehicles such as cars, airplanes, boats, or trains. By blocking histamine receptors in the brain and inner ear, cyclizine hydrochloride helps alleviate motion sickness symptoms and prevent their onset.
Nausea and Vomiting: Cyclizine hydrochloride is also used to relieve nausea and vomiting associated with various medical conditions, including viral gastroenteritis (stomach flu), inner ear disorders (such as labyrinthitis or vestibular neuritis), migraines, chemotherapy, and postoperative nausea and vomiting (PONV). It works by inhibiting the stimulation of the vomiting center in the brain and reducing the sensitivity of the inner ear to motion-induced nausea.
Vertigo: Cyclizine hydrochloride may be prescribed for the management of vertigo, a sensation of spinning or dizziness often caused by inner ear problems such as benign paroxysmal positional vertigo (BPPV), Meniere's disease, or vestibular migraine. By exerting antihistaminic and anticholinergic effects, cyclizine hydrochloride helps alleviate vertigo symptoms and improve balance and stability in affected individuals.
Dosage and Administration: Cyclizine hydrochloride is typically administered orally in the form of tablets or syrup. The dosage and frequency of administration depend on factors such as the severity of nausea or vomiting, the individual patient's response to treatment, and any underlying medical conditions. It is usually taken before travel or as needed to relieve symptoms. Cyclizine hydrochloride may also be administered intravenously (IV) in certain clinical settings, such as PONV prophylaxis in surgical patients.
Side Effects: Common side effects of cyclizine hydrochloride may include drowsiness, dizziness, dry mouth, blurred vision, constipation, and urinary retention. Less commonly, it may cause anticholinergic effects such as tachycardia (rapid heart rate), palpitations, confusion, and hallucinations. Rare but serious side effects may include allergic reactions, cardiac arrhythmias, and extrapyramidal symptoms (such as dystonia or tremor). Patients should be monitored for side effects during cyclizine hydrochloride therapy, and treatment should be adjusted or discontinued if adverse reactions occur.
Contraindications and Precautions: Cyclizine hydrochloride should be used with caution in patients with certain medical conditions, including glaucoma, urinary retention, prostatic hypertrophy, epilepsy, liver disease, and cardiovascular disorders. It is contraindicated in individuals with hypersensitivity to cyclizine hydrochloride or related compounds. Cyclizine hydrochloride may also interact with other medications, particularly central nervous system depressants, anticholinergic drugs, and monoamine oxidase inhibitors (MAOIs), increasing the risk of adverse effects or drug interactions.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| Taxonomy | Rank | Effect | Citations | Notation |
|---|---|---|---|---|
| unclassified Robinsoniella | no rank | Decreases | ⚗️ Source Study | |
| unclassified Fusobacterium | no rank | Decreases | ⚗️ Source Study | |
| unclassified Negativicoccus | no rank | Decreases | ⚗️ Source Study | |
| Eggerthellales | order | Decreases | ⚗️ Source Study | |
| Anaerofustis stercorihominis | species | Decreases | ⚗️ Source Study | |
| Asaccharospora irregularis | species | Decreases | ⚗️ Source Study | |
| Negativicoccus sp. S5-A15 | species | Decreases | ⚗️ Source Study | |
| Paraprevotella clara | species | Decreases | ⚗️ Source Study | |
| Slackia sp. NATTS | species | Decreases | ⚗️ Source Study | |
| Pseudoflavonifractor capillosus | species | Decreases | ⚗️ Source Study | |
| [Collinsella] massiliensis | species | Decreases | ⚗️ Source Study | |
| Parvibacter caecicola | species | Decreases | ⚗️ Source Study | |
| Coriobacterineae | suborder | Decreases | ⚗️ Source Study | |
| Chlamydiae/Verrucomicrobia group | superphylum | Decreases | ⚗️ Source Study |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Chronic Fatigue Syndrome | 0.1 | 0.1 | |
| Depression | 0.3 | 0.3 | |
| ME/CFS without IBS | 0.1 | 0.1 | |
| Mood Disorders | 0.3 | 0.3 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.